MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$7,803M
Net Income
-$10,496M
Net Profit Margin
-134.51%
EPS
-$8.45
Unit: Million (M) dollars
Revenue Breakdown
Product
Royalty Contract And Other
Revenue Breakdown
US
Europe
Rest Of World
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
7,803
6,960
7,925
7,769
Cost of goods sold
1,579
1,445
1,624
1,569
Research and development expenses
1,764
1,372
1,583
1,346
Acquired in-process research and development expenses
11,183
107
540
170
In-process research and development impairments
1,750
-
400
0
Selling, general and administrative expenses
1,921
1,451
1,794
1,357
Total costs and expenses
18,197
4,374
5,941
4,442
Operating (loss) income
-10,394
2,586
1,984
3,327
Interest expense
247
240
254
256
Other (income) expense, net
387
235
349
569
(loss) income before income taxes
-10,254
2,580
2,077
3,641
Income tax expense at u.s. federal statutory tax rate
-
-
88*
-
State taxes, net of federal benefit
-
-
-34*
-
Tax rate differential-IE
-
-
-29*
-
Other-IE
-
-
0*
-
Tax rate differential-Foreign Tax Jurisdiction Other
-
-
-2*
-
Global intangible low-taxed income
-
-
21*
-
Foreign-derived intangible income
-
-
21*
-
U.s. taxation of foreign branches
-
-
2*
-
Effective Income Tax Rate Reconciliation Cross Border Other Amount
-
-
1*
-
R&d tax credits
-
-
36*
-
Income Tax Reconciliation Tax Credits Other
-
-
2*
-
Valuation allowance-US
-
-
-134*
-
Acquired ipr&d and related charges
-
-
16*
-
Income Tax Reconciliation Nondeductible Expense Other
-
-
5*
-
Changes in unrecognized tax benefits
-
-
15*
-
Settlement of tax examinations
-
-
0*
-
Legal entity restructuring
-
-
0*
-
Other-US
-
-
7*
-
Income tax expense
242
559
-105
589
Net income
-
-
2,183
3,052
Net loss attributable to noncontrolling interest
-
-
0
0
Net (loss) income
-10,496
2,021
2,183
3,052
Basic EPS
-8.45
1.63
1.758
2.46
Diluted EPS
-8.45
1.61
1.744
2.43
Basic Average Shares
1,243,000,000
1,242,000,000
1,242,000,000
1,243,000,000
Diluted Average Shares
1,243,000,000
1,254,000,000
1,252,000,000
1,254,000,000
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net (loss) income
-$10,496M
(-635.51%↓ Y/Y)
US
$5,601M
(11.18%↑ Y/Y)
Europe
$1,155M
(-1.95%↓ Y/Y)
Rest Of World
$872M
(4.06%↑ Y/Y)
Europe
$169M
(1590.00%↑ Y/Y)
Rest Of World
$4M
(0.00%↑ Y/Y)
US
$2M
(-84.62%↓ Y/Y)
(loss) income before
income taxes
-$10,254M
(-522.15%↓ Y/Y)
Income tax expense
$242M
(-48.29%↓ Y/Y)
Other (income)
expense, net
$387M
(86.06%↑ Y/Y)
Product
$7,627M
(8.12%↑ Y/Y)
Royalty Contract And
Other
$176M
(551.85%↑ Y/Y)
Operating (loss) income
-$10,394M
(-520.13%↓ Y/Y)
Total revenues
$7,803M
(10.18%↑ Y/Y)
Interest expense
$247M
(-2.76%↓ Y/Y)
Total costs and
expenses
$18,197M
(294.90%↑ Y/Y)
Acquired in-process
research and development...
$11,183M
(18232.79%↑ Y/Y)
Selling, general and
administrative expenses
$1,921M
(40.73%↑ Y/Y)
Research and development
expenses
$1,764M
(18.31%↑ Y/Y)
In-process research and
development impairments
$1,750M
(821.05%↑ Y/Y)
Cost of goods sold
$1,579M
(5.20%↑ Y/Y)
Buy us a coffee
Gilead_Sciences_Logo-svg
GILEAD SCIENCES, INC. (GILD)
Gilead_Sciences_Logo-svg
GILEAD SCIENCES, INC. (GILD)